CNTX
Context Therapeutics Inc.
Biotechnology
Market Cap$214M
5Y Perf.-59.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CNTX vs AGIO
Revenue, margins, valuation, and 5-year total return — side by side.
AGIO
Agios Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.64B
5Y Perf.-41.4%
CNTX vs AGIO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTX | AGIO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $214M | $1.64B |
| Revenue (TTM) | $0.00 | $66M |
| Net Income (TTM) | $-40M | $-423M |
| Gross Margin | — | 82.1% |
| Operating Margin | — | -7.2% |
| Total Debt | $112K | $62M |
| Cash & Equiv. | $66M | $89M |
CNTX vs AGIO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTX
AGIO
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Context Therapeutic… (CNTX) | 100 | 40.5 | -59.5% |
| Agios Pharmaceutica… (AGIO) | 100 | 58.6 | -41.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTX vs AGIO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CNTX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Agios Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CNTX
Context Therapeutics Inc.
The Income Pick
CNTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.46
- EPS growth 17.4%
- Lower volatility, beta 0.46, Low D/E 0.2%, current ratio 8.52x
Best for: income & stability and growth exposure
AGIO
Agios Pharmaceuticals, Inc.
The Long-Run Compounder
AGIO is the clearest fit if your priority is long-term compounding.
- -42.2% 10Y total return vs CNTX's -54.3%
- 48.0% revenue growth vs CNTX's -45.5%
- -31.7% ROA vs CNTX's -54.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs CNTX's -45.5% |
| Quality / Margins | CNTX | 4.9% margin vs AGIO's -6.4% |
| Stability / Safety | CNTX | Beta 0.46 vs AGIO's 1.12, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CNTX | +201.4% vs AGIO's -2.4% |
| Efficiency (ROA) | AGIO | -31.7% ROA vs CNTX's -54.8% |
CNTX vs AGIO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CNTX vs AGIO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCNTXLAGGINGAGIO
AGIOAgios Pharmaceuticals…
1leads
CNTXContext Therapeutics …
3leads
6 Total Categories
CATEGORYLEADERvs AGIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AGIO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CNTX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CNTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
CNTX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AGIO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AGIO and CNTX operate at a comparable scale, with $66M and $0 in trailing revenue.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $66M |
| EBITDAEarnings before interest/tax | -$43M | -$470M |
| Net IncomeAfter-tax profit | -$40M | -$423M |
| Free Cash FlowCash after capex | -$21M | -$385M |
| Gross MarginGross profit ÷ Revenue | — | +82.1% |
| Operating MarginEBIT ÷ Revenue | — | -7.2% |
| Net MarginNet income ÷ Revenue | — | -6.4% |
| FCF MarginFCF ÷ Revenue | — | -5.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +137.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -80.0% | -9.0% |
AGIO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CNTX and AGIO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $214M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $148M | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | -3.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 30.30x |
| Price / BookPrice ÷ Book value/share | 3.67x | 1.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CNTX and AGIO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CNTX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
AGIO delivers a -34.1% return on equity — every $100 of shareholder capital generates $-34 in annual profit, vs $-60 for CNTX. CNTX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AGIO's 0.05x. On the Piotroski fundamental quality scale (0–9), CNTX scores 3/9 vs AGIO's 2/9, reflecting mixed financial health.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -60.0% | -34.1% |
| ROA (TTM)Return on assets | -54.8% | -31.7% |
| ROICReturn on invested capital | — | -26.3% |
| ROCEReturn on capital employed | -50.9% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.05x |
| Net DebtTotal debt minus cash | -$66M | -$27M |
| Cash & Equiv.Liquid assets | $66M | $89M |
| Total DebtShort + long-term debt | $112,064 | $62M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
CNTX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CNTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AGIO five years ago would be worth $4,935 today (with dividends reinvested), compared to $4,569 for CNTX. Over the past 12 months, CNTX leads with a +201.4% total return vs AGIO's -2.4%. The 3-year compound annual growth rate (CAGR) favors CNTX at 56.7% vs AGIO's 2.7% — a key indicator of consistent wealth creation.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +50.3% | +1.3% |
| 1-Year ReturnPast 12 months | +201.4% | -2.4% |
| 3-Year ReturnCumulative with dividends | +285.1% | +8.3% |
| 5-Year ReturnCumulative with dividends | -54.3% | -50.7% |
| 10-Year ReturnCumulative with dividends | -54.3% | -42.2% |
| CAGR (3Y)Annualised 3-year return | +56.7% | +2.7% |
CNTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
CNTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CNTX is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than AGIO's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNTX currently trades 64.4% from its 52-week high vs AGIO's 59.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 1.12x |
| 52-Week HighHighest price in past year | $3.62 | $46.00 |
| 52-Week LowLowest price in past year | $0.49 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +59.8% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 901K | 1.0M |
CNTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CNTX as "Buy" and AGIO as "Buy". Consensus price targets imply 125.3% upside for CNTX (target: $5) vs 37.1% for AGIO (target: $38).
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $5.25 | $37.75 |
| # AnalystsCovering analysts | 6 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CNTX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). AGIO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallContext Therapeutics Inc. (CNTX)Leads 3 of 6 categories
Loading custom metrics...
CNTX vs AGIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CNTX or AGIO a better buy right now?
Analysts rate Context Therapeutics Inc.
(CNTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CNTX or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc.
(AGIO) delivered a total return of -50. 7%, compared to -54. 3% for Context Therapeutics Inc. (CNTX). Over 10 years, the gap is even starker: AGIO returned -42. 2% versus CNTX's -54. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CNTX or AGIO?
By beta (market sensitivity over 5 years), Context Therapeutics Inc.
(CNTX) is the lower-risk stock at 0. 46β versus Agios Pharmaceuticals, Inc. 's 1. 12β — meaning AGIO is approximately 143% more volatile than CNTX relative to the S&P 500. On balance sheet safety, Context Therapeutics Inc. (CNTX) carries a lower debt/equity ratio of 0% versus 5% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CNTX or AGIO?
On earnings-per-share growth, the picture is similar: Context Therapeutics Inc.
grew EPS 17. 4% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CNTX or AGIO?
Context Therapeutics Inc.
(CNTX) is the more profitable company, earning 0. 0% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNTX leads at 0. 0% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CNTX or AGIO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CNTX or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Context Therapeutics Inc.
(CNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Both have compounded well over 10 years (CNTX: -54. 3%, AGIO: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CNTX and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNTX is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.